.png)
ABOUT US
Innovators
Metabolica Health is a preclinical biotech company developing a first-in-class, oral therapy for diabetes, obesity, and metabolic liver disease. Our approach is rooted in the microbiome: we’re advancing a small molecule, 4-cresol, that restores the body’s ability to produce insulin and rebalance metabolism.
​
Unlike current treatments that manage symptoms, we target the biological root of disease — with regenerative effects on the insulin-producing pancreatic β-cells and broader benefits across systemic metabolism.
​
Backed by peer-reviewed publications, a granted U.S. patent, and global academic partnerships, Metabolica is building a scalable therapeutic platform with broad clinical potential and clear translational focus.
​
Our leadership team combines deep scientific expertise with operational and business experience to translate discovery into real-world impact.
Daniel Auld, Ph.D.
President, CEO & Director
Dr. Auld brings over 20 years of experience in neuroscience, drug development, and institutional leadership. He has co-led operations at McGill’s Victor Phillip Dahdaleh Institute of Genomic Medicine since 2011, holds two patents, and is a graduate of the adMare Executive Institute. He earned his Ph.D. from McGill and has published in journals including Nature.
​
Scott Jardin, CPA, CGA
Chief Financial Officer
Mr. Jardin is a seasoned financial executive with experience across biotech, regulated consumer health, and academic research. He currently serves as CFO of The Good Shroom Co. and Teonan Biomedical, and previously led AAA Medic Montreal as CEO. He also managed finance operations for McGill University’s research centres. He holds a B.Comm from Concordia University and graduate diplomas in Finance and IT from McGill and UQAM.
​
Roy Bonnel
Executive Chairman & Director
Mr. Bonnell brings over 30 years of leadership in capital markets, natural resources, and venture investment. He holds an LL.B. from Western University, an MSc from the London School of Economics, and an MBA from McGill. He is a member of the Law Society of Upper Canada.
​
Edward Ierfino
Director
Mr. Ierfino is a capital markets advisor with over 15 years of experience in public company financing, investor relations, and strategic growth. As President of EGI Holdings, he advises companies in the health and wellness sectors. He has served on TSX Venture boards and founded two Capital Pool Companies. He holds a B.Comm in Finance from Concordia University.​
Graham Wood, Ph.D.
Director
Dr. Wood is a distinguished expert in clinical pharmacology with extensive leadership in biotech and pharmaceutical companies. He currently serves as Executive Vice-President of Nucleus Network (U.S.), overseeing U.S. operations and services. He earned his Ph.D. in Neurology and Neurosurgery from McGill University and a B.Sc. in Biochemistry from McMaster University.
Dominique Gauguier, Ph.D.
Scientific Advisor/ Professor, Université Paris-CitéDr. Gauguier is an internationally recognized expert in metabolic disease genetics and a pioneer in the discovery of 4-cresol’s therapeutic potential. He is Director of Research at INSERM (Université Paris–Cité), and holds visiting and adjunct positions at Imperial College London, Kyoto University, and McGill University. He earned his Ph.D. in human nutrition in Paris and previously served as Professor of Mammalian Genetics at the University of Oxford.
CAREERS
Join Us
As a growing Biotechnology Startup, we are always looking for new team members. Whether you’re interested in business or have something innovative and unique to bring to the table, we’d love to see if you’re a good fit for Metabolica Health. Send us your CV today to and we will get back to you as soon as we can.